Clinical Trial · NCT05823402

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)

Overview

The SPECTacular study will enroll patients who are already undergoing a FDA approved PSMA-targeted Radioligand treatment cycle. During each treatment cycle, patients will receive 5 additional SPECT/CT scans to investigate the limits of agreement between dosimetry (absorbed radiation dose) approximation methods and dosimetry using the triexponential fitting method.

Sponsor

GE Healthcare

Phase

N/A

ClinicalTrials.gov

NCT05823402

Eligibility

Inclusion

Ability to lay flat on scanner for duration of SPECT-CT imaging studies (1-2 hours)
Histologically or pathologically confirmed prostate adenocarcinoma without predominant small cell component.
Stated willingness to comply with all study procedures and availability for the duration of the study
Patient is receiving PSMA-targeted Radioligand Therapy (PRLT) for treatment of PSMA-positive tumor and/or metastases of prostate cancer. Therapy may be FDA approved or investigational in nature under an approved clinical trial.

Exclusion

Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 2
Assessment by the Investigator as unable or unwilling to comply with the requirements of the protocol.
All criteria which may preclude a PSMA-radioligand therapy using Lu-177 PSMA-617 or Lu-177 PSMA I\&T to be performed as per standardized guidelines and protocols laid down for these treatments and per decision by the treating physician.